Abstract
The primary research goal of the Lung Cancer Committee is to conduct clinical trials that improve the survival rate of patients with locally advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) without increasing the treatment-related morbidity. The secondary goals are to reduce the treatment toxicity, improve patients’ quality of life, develop treatment strategies for high-risk patient subgroups, conduct correlative and translational research, and clarify the prognostic factors by analyzing the large RTOG lung cancer patient database.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
